Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 169

1.

DOT1L-HES6 fusion drives androgen independent growth in prostate cancer.

Annala M, Kivinummi K, Leinonen K, Tuominen J, Zhang W, Visakorpi T, Nykter M.

EMBO Mol Med. 2014 Jul 8. pii: e201404210. doi: 10.15252/emmm.201404210. [Epub ahead of print] No abstract available.

PMID:
25006183
[PubMed - as supplied by publisher]
Free Article
2.

Hypermethylation of the GABRE~miR-452~miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy.

Kristensen H, Haldrup C, Strand S, Mundbjerg K, Mortensen MM, Thorsen K, Ostenfeld MS, Wild PJ, Arsov C, Goering W, Visakorpi T, Egevad L, Lindberg J, Grönberg H, Høyer S, Borre M, Ørntoft TF, Sørensen KD.

Clin Cancer Res. 2014 Apr 15;20(8):2169-81. doi: 10.1158/1078-0432.CCR-13-2642.

PMID:
24737792
[PubMed - in process]
3.

A prostate cancer susceptibility allele at 6q22 increases RFX6 expression by modulating HOXB13 chromatin binding.

Huang Q, Whitington T, Gao P, Lindberg JF, Yang Y, Sun J, Väisänen MR, Szulkin R, Annala M, Yan J, Egevad LA, Zhang K, Lin R, Jolma A, Nykter M, Manninen A, Wiklund F, Vaarala MH, Visakorpi T, Xu J, Taipale J, Wei GH.

Nat Genet. 2014 Feb;46(2):126-35. doi: 10.1038/ng.2862. Epub 2014 Jan 5.

PMID:
24390282
[PubMed - indexed for MEDLINE]
4.

Long noncoding RNA in prostate, bladder, and kidney cancer.

Martens-Uzunova ES, Böttcher R, Croce CM, Jenster G, Visakorpi T, Calin GA.

Eur Urol. 2014 Jun;65(6):1140-51. doi: 10.1016/j.eururo.2013.12.003. Epub 2013 Dec 14.

PMID:
24373479
[PubMed - in process]
5.

USP22 regulates oncogenic signaling pathways to drive lethal cancer progression.

Schrecengost RS, Dean JL, Goodwin JF, Schiewer MJ, Urban MW, Stanek TJ, Sussman RT, Hicks JL, Birbe RC, Draganova-Tacheva RA, Visakorpi T, DeMarzo AM, McMahon SB, Knudsen KE.

Cancer Res. 2014 Jan 1;74(1):272-86. doi: 10.1158/0008-5472.CAN-13-1954. Epub 2013 Nov 6.

PMID:
24197134
[PubMed - indexed for MEDLINE]
6.

Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer.

Leinonen KA, Saramäki OR, Furusato B, Kimura T, Takahashi H, Egawa S, Suzuki H, Keiger K, Ho Hahm S, Isaacs WB, Tolonen TT, Stenman UH, Tammela TL, Nykter M, Bova GS, Visakorpi T.

Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2333-44. doi: 10.1158/1055-9965.EPI-13-0333-T. Epub 2013 Oct 1.

PMID:
24083995
[PubMed - in process]
Free PMC Article
7.

Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells.

Khanna A, Kauko O, Böckelman C, Laine A, Schreck I, Partanen JI, Szwajda A, Bormann S, Bilgen T, Helenius M, Pokharel YR, Pimanda J, Russel MR, Haglund C, Cole KA, Klefström J, Aittokallio T, Weiss C, Ristimäki A, Visakorpi T, Westermarck J.

Cancer Res. 2013 Nov 15;73(22):6757-69. doi: 10.1158/0008-5472.CAN-13-1002. Epub 2013 Sep 26.

PMID:
24072747
[PubMed - indexed for MEDLINE]
8.

DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer.

Haldrup C, Mundbjerg K, Vestergaard EM, Lamy P, Wild P, Schulz WA, Arsov C, Visakorpi T, Borre M, Høyer S, Orntoft TF, Sørensen KD.

J Clin Oncol. 2013 Sep 10;31(26):3250-8. doi: 10.1200/JCO.2012.47.1847. Epub 2013 Aug 5.

PMID:
23918943
[PubMed - indexed for MEDLINE]
9.

The mutational landscape of prostate cancer.

Barbieri CE, Bangma CH, Bjartell A, Catto JW, Culig Z, Grönberg H, Luo J, Visakorpi T, Rubin MA.

Eur Urol. 2013 Oct;64(4):567-76. doi: 10.1016/j.eururo.2013.05.029. Epub 2013 May 18. Review.

PMID:
23759327
[PubMed - indexed for MEDLINE]
10.

STAT5A/B gene locus undergoes amplification during human prostate cancer progression.

Haddad BR, Gu L, Mirtti T, Dagvadorj A, Vogiatzi P, Hoang DT, Bajaj R, Leiby B, Ellsworth E, Blackmon S, Ruiz C, Curtis M, Fortina P, Ertel A, Liu C, Rui H, Visakorpi T, Bubendorf L, Lallas CD, Trabulsi EJ, McCue P, Gomella L, Nevalainen MT.

Am J Pathol. 2013 Jun;182(6):2264-75. doi: 10.1016/j.ajpath.2013.02.044. Epub 2013 May 7.

PMID:
23660011
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Bcl-2 associated athanogene 5 (Bag5) is overexpressed in prostate cancer and inhibits ER-stress induced apoptosis.

Bruchmann A, Roller C, Walther TV, Schäfer G, Lehmusvaara S, Visakorpi T, Klocker H, Cato AC, Maddalo D.

BMC Cancer. 2013 Mar 1;13:96. doi: 10.1186/1471-2407-13-96.

PMID:
23448667
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma.

Parker BC, Annala MJ, Cogdell DE, Granberg KJ, Sun Y, Ji P, Li X, Gumin J, Zheng H, Hu L, Yli-Harja O, Haapasalo H, Visakorpi T, Liu X, Liu CG, Sawaya R, Fuller GN, Chen K, Lang FF, Nykter M, Zhang W.

J Clin Invest. 2013 Feb 1;123(2):855-65. doi: 10.1172/JCI67144. Epub 2013 Jan 9.

PMID:
23298836
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

HOXB13 G84E mutation in Finland: population-based analysis of prostate, breast, and colorectal cancer risk.

Laitinen VH, Wahlfors T, Saaristo L, Rantapero T, Pelttari LM, Kilpivaara O, Laasanen SL, Kallioniemi A, Nevanlinna H, Aaltonen L, Vessella RL, Auvinen A, Visakorpi T, Tammela TL, Schleutker J.

Cancer Epidemiol Biomarkers Prev. 2013 Mar;22(3):452-60. doi: 10.1158/1055-9965.EPI-12-1000-T. Epub 2013 Jan 4.

PMID:
23292082
[PubMed - indexed for MEDLINE]
Free Article
14.

Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes.

Augello MA, Burd CJ, Birbe R, McNair C, Ertel A, Magee MS, Frigo DE, Wilder-Romans K, Shilkrut M, Han S, Jernigan DL, Dean JL, Fatatis A, McDonnell DP, Visakorpi T, Feng FY, Knudsen KE.

J Clin Invest. 2013 Jan 2;123(1):493-508. doi: 10.1172/JCI64750. Epub 2012 Dec 21.

PMID:
23257359
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Expression of ERG oncoprotein is associated with a less aggressive tumor phenotype in Japanese prostate cancer patients.

Kimura T, Furusato B, Miki J, Yamamoto T, Hayashi N, Takahashi H, Kamata Y, van Leenders GJ, Visakorpi T, Egawa S.

Pathol Int. 2012 Nov;62(11):742-8. doi: 10.1111/pin.12006.

PMID:
23121605
[PubMed - indexed for MEDLINE]
16.

Detection of smell print differences between nonmalignant and malignant prostate cells with an electronic nose.

Roine A, Tolvanen M, Sipiläinen M, Kumpulainen P, Helenius MA, Lehtimäki T, Vepsäläinen J, Keinänen TA, Häkkinen MR, Koskimäki J, Veskimäe E, Tuokko A, Visakorpi T, Tammela TL, Sioris T, Paavonen T, Lekkala J, Helle H, Oksala NK.

Future Oncol. 2012 Sep;8(9):1157-65. doi: 10.2217/fon.12.93.

PMID:
23030490
[PubMed - indexed for MEDLINE]
17.

The role of genetic markers in the management of prostate cancer.

Choudhury AD, Eeles R, Freedland SJ, Isaacs WB, Pomerantz MM, Schalken JA, Tammela TL, Visakorpi T.

Eur Urol. 2012 Oct;62(4):577-87. doi: 10.1016/j.eururo.2012.05.054. Epub 2012 Jun 5. Review.

PMID:
22695242
[PubMed - indexed for MEDLINE]
18.

Goserelin and bicalutamide treatments alter the expression of microRNAs in the prostate.

Lehmusvaara S, Erkkilä T, Urbanucci A, Jalava S, Seppälä J, Kaipia A, Kujala P, Lähdesmäki H, Tammela TL, Visakorpi T.

Prostate. 2013 Jan;73(1):101-12. doi: 10.1002/pros.22545. Epub 2012 Jun 5.

PMID:
22674191
[PubMed - indexed for MEDLINE]
19.

Novel endocrine aspects of prostate cancer.

Visakorpi T.

Mol Cell Endocrinol. 2012 Sep 5;360(1-2):1-2. doi: 10.1016/j.mce.2012.03.015. Epub 2012 Mar 28. No abstract available.

PMID:
22465021
[PubMed - indexed for MEDLINE]
20.

Chemical castration and anti-androgens induce differential gene expression in prostate cancer.

Lehmusvaara S, Erkkilä T, Urbanucci A, Waltering K, Seppälä J, Larjo A, Tuominen VJ, Isola J, Kujala P, Lähdesmäki H, Kaipia A, Tammela TLj, Visakorpi T.

J Pathol. 2012 Jul;227(3):336-45. doi: 10.1002/path.4027. Epub 2012 May 8.

PMID:
22431170
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk